

Alcon becomes a separately traded standalone company

On April 9, 2019 Alcon becomes a separately traded company. Novartis and Alcon are now positioned to capitalize on significant growth opportunities and focus resources on their respective businesses and strategic priorities.

Apr 09, 2019

Media Release

Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off.

[Read More](#)

Video - The future of Novartis

Our future is as a leading focused medicines company, powered by data science and advanced therapy platforms. CEO Vas Narasimhan shares our vision.

Vas on Instagram



vasnarasimhan
13.6K followers

[View profile](#)



Reimagining Novartis



[View more on Instagram](#)



474 likes

[vasnarasimhan](#)

In the life of a leader and in business, change is constant. With your purpose as your guiding light, you continuously have to iterate and evolve to meet the changing needs around you. That is a lesson I learned early on in my career, and it changed not only my career trajectory but also the way I see the world.

Today is a big day for Novartis and for me personally as CEO. When I took over as CEO last year, I challenged our entire company to reimagine Novartis for the future. We set a vision to become a more focused medicines company powered by data science and advanced therapy platforms - and today, with the spin-off of Alcon, our former eye-care devices unit, we've taken a major step toward realizing that vision. Novartis is now better positioned than we ever have been to reimagine medicine for patients all around the world. The spin-off allows us to focus our energy on innovating the latest advancements to transform human health, and I'm excited for our associates, for our investors, and most importantly, for patients because of the impact that we could have.

[#reimaginingmedicine](#) [#ReimaginingNovartis](#) [#OneNovartis](#) [#Novartislife](#) [#speech](#) [#speaking](#)
[#amazing](#) [#bestoftheday](#) [#happy](#) [#inspiration](#) [#work](#)

[@novartis](#)

[View all 7 comments](#)

Add a comment...

In Pictures

Alcon lists on the SIX Swiss Exchange and New York Stock Exchange (NYSE)



Novartis CFO Harry Kirsch and Alcon Chairman Mike Ball at the SIX Swiss Exchange in Zürich.

NYSE tweeted pictures of the Alcon team in New York

Additional Resources

[New Alcon website](#)

[Download the Swiss Listing Prospectus \(PDF 2.2 MB\)](#)

[Download the Supplement to the Swiss Listing Prospectus \(PDF 0.4 MB\)](#)

[Download the Alcon 20-F \(PDF 2.0 MB\)](#)

[Download the Form 6-K: Alcon Appoints Senior Leaders in Final Preparation for Spin-off \(PDF 0.1 MB\)](#)

[Download the Form 8937: Basis of Securities \(PDF 0.1 MB\)](#)

Source URL: <https://prod1.novartis.com/news/alcon-becomes-separately-traded-standalone-company>

List of links present in page

1. <https://prod1.novartis.com/news/alcon-becomes-separately-traded-standalone-company>
2. <https://prod1.novartis.com/news/media-releases/novartis-continues-transformation-leading-medicines-company-completion-alcon-spin>
3. <https://www.alcon.com/>
4. https://prod1.novartis.com/sites/novartis_com/files/alcon-swiss-listing-prospectus.pdf
5. https://prod1.novartis.com/sites/novartis_com/files/alcon-supplement-to-the-swiss-listing-prospectus.pdf
6. https://prod1.novartis.com/sites/novartis_com/files/alcon-20f-filing-2019.pdf
7. https://prod1.novartis.com/sites/novartis_com/files/alcon-inc-6-k.pdf
8. https://prod1.novartis.com/sites/novartis_com/files/alcon-form-8937.pdf